Discover
ELVN
Enliven Therapeutics, Inc.
48.76
2 x 35.90
2 x 62.23
bid
ask
-
1.99
3.92%
2 @ 04:00 PM
47.96 -0.80 (1.64%)
| Ytd | 216.62% | |
| 1y | 148.14% |
48.20
day range
51.84
14.79
52 week range
52.39
| Open | 51.20 | Prev Close | 50.75 | Low | 48.20 | High | 51.84 | Mkt Cap | 3.48B |
| Vol | 1.06M | Avg Vol | 1.38M | EPS | -1.64 | P/E | N/A | Forward P/E | -20.88 |
| Beta | 0.40 | Short Ratio | 3.89 | Inst. Own | 89.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 42.32 | 200-d Avg | 29.39 | 1yr Est | 62.89 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0 | N/A | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-12 | 2025-09 | 0 | N/A | 0.11 | 25.58% |
| 2025-11-12 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-13 | 2025-06 | 0 | N/A | 0.04 | 7.55% |
| 2025-08-13 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-01 | Stifel | Upgrade | Buy | Buy |
| 2026-06-29 | Jones Trading | Upgrade | Buy | Buy |
| 2026-06-09 | Stifel | Upgrade | Buy | |
| 2026-06-02 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-05-08 | Goldman Sachs | Upgrade | Buy | Buy |
| 2026-03-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-07 | BALLAL RAHUL D. | Director | 22.34K | Sale |
| 2026-06-16 | COLLINS HELEN LOUISE | Officer | 25.00K | Sale |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-06-16 | HOHL BENJAMIN | Chief Financial Officer | 51.00K | Sale |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
| 2026-06-04 | KUNKEL LORI ANNE | Director | 51.88K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Orbimed Advisors LLC. | 7.96M | 388.11M | 13.07% |
| 2026-03-30 | FMR, LLC | 6.83M | 332.99M | 11.21% |
| 2026-03-30 | Polar Capital Holdings PLC | 5.07M | 247.01M | 8.32% |
| 2026-03-30 | Blackrock Inc. | 3.68M | 179.67M | 6.05% |
| 2026-03-30 | Commodore Capital Lp | 3.28M | 159.69M | 5.38% |
| 2026-03-30 | Vestal Point Capital, LP | 3.25M | 158.47M | 5.34% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.62M | 78.81M | 2.65% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.12M | 54.61M | 1.84% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.07M | 52.31M | 1.76% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 928.33K | 45.27M | 1.52% |
| 2026-04-29 | Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 773.81K | 37.73M | 1.27% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 569.80K | 27.78M | 0.94% |